A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.

Trial Profile

A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Buparlisib (Primary) ; Bevacizumab
  • Indications Renal cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 19 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 19 May 2016 Results published in the Cancer
    • 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top